# Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer

> **NCT03370367** · PHASE3 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 189 (actual)

## Conditions studied

- Stage I-II Head and Neck Cancer

## Interventions

- **DRUG:** 13-cis retinoic acid
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03370367
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1989-05-15
- **Primary completion:** 1999-01-15
- **Final completion:** 2015-04-14
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370367, "Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03370367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*